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after the invasive treatment and the idea of having 
intercourse 3 time a week is often too much for a couple.  
Moreover, again the fear of pain makes both the women and 
her partner reluctant for even trying intercourse. 
In the literature we find that women who have been 
irradiated in the pelvic region express a need for information 
about the consequences of radiation therapy in terms of 
possible vaginal and sexual changes. Others have added that 
interventions aiming at improving (sexual) health have to 
take into account different aspects, e.g.,  the relationship, 
body-image, sexual identity and vaginal changes. Others 
revealed that women and their partners need individually 
tailored information and - practical advice about the side-
effects of the treatment including a focus on sexual 
rehabilitation. 
Based on a qualitative study, Cullen et al. (2013) formulated 
the following eight recommendations for professional 
counseling with women undergoing pelvic radiation therapy :  
  
1. Introduce the dilator in a light and straightforward 
manner 
2. Enhance dilator accessibility 
3. Introduce the vaginal dilator early on in treatment 
4. Emphasize (vaginal) health maintenance over 
intercourse as a benefit of dilator use 
5. Explore and acknowledge women’s values and 
views of sexuality 
6. Increase awareness and sensitivity to emotional 
reactions 
7. Enhance psychological educational resources for 
supporting vaginal dilator use 
8. Ensure consistent institutional practice when 
introducing the dilator 
During my talk, I will describe in more detail how these 
recommendations can be used in daily practice based on my 
experience in the University Hospital of Leuven, Belgium. 
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Purpose/Objective: Lung cancer (LC) has a significant impact 
on patients' health-related quality of life (HRQOL). This study 
aimed to investigate the correlations among patient, tumor, 
and pre-radiation therapy treatment factors and the global 
health status (GHS) and functional scales scores reported by 
LC patients before radiation therapy (RT). In addition, we 
investigated whether the pre-RT HRQOL assessment impacts 
in survival. 
Materials and Methods: We conducted a prospective 
multicentric study with a quality-of-life survey on 171 LC 
patients just before starting radiation treatment. HRQOL was 
assessed using the EORTC-QLQ-C30 (v3.0) questionnaire and 
GHS, physical (PF), role (RF), emotional (EF), cognitive (CF), 
and social functioning (SF) scores were evaluated. Several 
patient factors (age, sex, Karnofsky performance status 
[KPS], weight loss, duration of symptoms before diagnosis, 
living distances from homes to hospitals, respiratory/cardiac 
comorbidities, and smoking habits), tumor features 
(histology, stage), and other treatments before RT (induction 
chemotherapy and surgery) were considered for the analysis. 
Multivariate analyses were performed by using a logistic 
regression model, with a stepwise backward elimination 
procedure. 
Results: The median age at diagnosis was 63 years (range, 
35-89). The TNM classification was as follows: 7 I, 18 II, 129 
III, and 17 IV. The median GHS, PF, RF, EF, CF, and SF scores 
for the entire group of patients were 58%, 73%, 66%, 75%, 
83%, and 83%, respectively. In the multivariate analysis, 
patients losing weight prior to beginning RT reported lower 
GHS scores (OR 0.42; CI: 0.22-0.79; P = 0.007) and PF (OR 
0.41; CI: 0.22-0.76; P = 0.005). In terms of SF, patients 
reporting higher SF scores before treatment had a lower risk 
of mortality (OR 0.20; CI: 0.42-0.95; P = 0.043) and relapse 
(OR 0.30; CI: 0.10-0.88; P = 0.029). In addition, patients with 
non-adenocarcinoma LC reported lower SF (OR 0.31; CI: 0.14-
0.71; P = 0.005). Finally, patients who had induction 
chemotherapy reported higher EF scores (OR 2.00; CI: 1.06-
3.77; P = 0.031).  
Conclusions: Pre-RT HRQOL assessment associates with 
outcome in LC patients. Knowledge of these results may be 
used to assist the radiation oncology team to identify risk 
factors associated with lower HRQOL outcomes before RT and 
enable to make a collaborative multidisciplinary approach 
covering the specific needs for each patient.  
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Purpose/Objective: To evaluate the impact of variation of 
urinary symptoms and incontinence, prospectively evaluated 
by means of 2 validated questionnaires (QSTs), IPSS and ICIQ-
SF (hereafter ICIQ), in the first year after post-prostatectomy 
(PoP) radiotherapy (RT) end, on anxiety and depression 
(ANX/DEP) as measured by HADS (Hospital Anxiety and 
Depression Scale) questionnaire. 
Materials and Methods: In 2012 a prospective, observational, 
single Institute study for the evaluation of urinary toxicity 
from whole-pelvis RT (WPRT) was activated. This analysis 
pertains to the first 113 pts with available baseline (BSL) and 
end-RT IPSS, ICIQ and HADS QSTs. Median age was 66 years, 
median interval from prostatectomy to RT was 3.6 and 45 
months for the 63 and 50 pts treated with adjuvant and 
salvage intent, respectively. RT was delivered with static-
field IMRT, Tomotherapy and VMAT in 19, 54 and 41 pts, 
respectively, at conventional fractionation (CF, 1.8-2 Gy) in 
45 pts, and moderate hypofractionation (HYPO, median 2.35 
Gy/fraction) in 68. WPRT was delivered at 50.4 Gy/28 
fractions in CF, at 52.50 Gy/28 fractions in HYPO. Adjuvant 
androgen deprivation (AAD, median 2 years) was prescribed 
for 32 pts. The prevalence of clinically significant (score ≥8) 
anxiety (ANX≥8) and depression (DEP≥8) before (n=113), 
during (half, n=95), at RT end (n=115) and 3 (n=96), 6 (n=90) 
and 12 (n=72) months after its completion were considered. 
Wilcoxon tests were performed to find significant differences 
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between ANX≥8/DEP≥8 rates during/after RT vs BSL. The 
impact of ICIQ/IPSS scores, as well as that of BSL ANX/DEP, 
on the risk of ANX≥8/ DEP≥8 at 6-12 months was tested in a 
logistic regression model.  
Results: The rates of ANX≥8 did not differ from BSL at any 
time, though an increase was found at 3-6 months (6 months 
vs BSL: 23.3% vs 14.8%, p=0.12). On the contrary, DEP≥8 was 
significantly higher during and after RT (6 months vs BSL: 
22.2% vs 8.8%, p=0.02; difference at 12 months not 
statistically significant). No impact on ANX≥8/DEP≥8 of RT 
intent, fractionation, AAD or RT technique emerged at any 
time. 
ANX≥8 at 6-12 months was predicted by 2-variable models 
including BSL ANX and ICIQ scores at corresponding times or, 
alternatively, at RT end, with high discriminative power (AUC 
ranging between 0.86 and 0.90). The same variables also 
predicted DEP≥8 at 6 months (AUC=0.88). A further analysis 
showed that the changes in ANX≥8/DEP≥8 over time are 
highly modulated by ICIQ score (Figure1). 
 
Conclusions: Incontinence, during and after PoP WPRT, and 
baseline ANX/DEP are major factors in increasing the risk of 
clinically significant anxiety/depression. End RT ICIQ score is 
a good predictor of increased risk of ANX/DEP at 6-12 
months. 
   
 
Debate: Should participation to databases be made 
mandatory  
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Clinical decision is a complex moment and, as stated by Sir 
W.Osler, ‘Medicine is a science of uncertainty and an art of 
probability’. 
Medical doctors foster their ‘internal databases of 
knowledge’ by daily clinical practice, but time-by-time their 
performances question their capacity to storage and to 
communicate data, as well as to act efficiently.  
The rapid learning technology is nowadays supporting the 
transfer of this process to ‘external databases of knowledge’, 
with the aim to have less individual variability in the 
understanding of the knowledge and more reliability in the 
prediction of the outcomes.  
By rapid-learning technology data routinely generated 
through patient care and clinical research feed into an ever-
growing databank or set of coordinated databases. The 
health care system “learns” by routinely and iteratively 
collecting data in a planned and strategic manner, generating 
evidence through retrospective analysis of existing data as 
well as data from prospective studies and generating new 
hypotheses for investigation.  
Even if many issues in term of data definition, accuracy and 
interoperability are still to be solved this approach is not 
mandatory: it is unavoidable!  
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Big multi-institutional medical databases will be technically 
feasible in near future. The validity of such databases 
critically depends on uniform coding and comprehensive 
registration of all clinical relevant information including 
toxicity and long term follow up. Provided all technical 
problems and data protection issues could be solved, the 
question arises what kind of conclusion could be drawn from 
these databases for clinical oncology. Databases will give in 
realistic overview how cancer patients are treated in specific 
situations including the presumably high variability of the 
applied treatments. Clinical outcome data including toxicity 
and survival would give an impression, what can be achieved 
with currently available treatments. The widespread use of 
these databases will likely result in some potentially 
unbeneficial changes in clinical practice and a number of 
risks, if statistical analysis is preformed and causal 
interpretations is pursued. The universal availability of 
clinical outcomes in a big database will led to smaller 
variations of actually applied treatments, since presumably 
favorable treatments would be identified in these databases, 
and physician would prefer to prescribe, what most other 
physician prescribe in the same situation. These presumably 
favorable treatments were likely influenced by a number of 
biases resulting from preconceptions of the oncological 
community. Innovative treatments initiated by single 
investigators or institutes that don’t follow the 
preconceptions of the majority of the oncological community 
maybe hampered, if mainstream treatments derived from big 
databases are easily accessible for home physicians and 
patients. The risk that knowledge form big databases in 
absence of evidence from randomized trials results in self-
fulfilling prophecies is high. One important risk of 
misinterpretation results from the fact that clinical databases 
do typically not allow to perform an intent to treat analysis. 
Since complete documentation of all potentially criteria 
involved in treatment decisions cannot be comprehensively 
documented in a clinical database, the risk of 
misinterpretation is high. Propensity scores have been 
proposes to correct for these biases, but are unable to 
correct for unknown relationships. Whenever causal 
interpretations are derived from big clinical databases, one 
needs to be aware that interpretation requires a high degree 
of caution. Results from clinical big databases should be 
regarded as hypothesis generating and cannot at all be 
considered as substitute for randomized clinical trials. 
Forcing physicians, who have no intrinsic motivation, to 
